You are here

Article Text

Article menu

Download PDFPDF

ePoster Viewing
AS03. Cervical cancer
EP085/#241  Evaluation of HPV types among women enrolled in the mulher cervical cancer screening study in mozambique
Free
  1. Mila P Salcedo1,
  2. Cristina Oliveira2,
  3. Nafissa Osman3,
  4. Ellen Baker1,
  5. Andrea Neves4,
  6. Ricardina Rangeiro5,
  7. Arlete Mariano6,
  8. Joseph Thomas7,
  9. Viviane Andrade8,
  10. Jennifer Carns9,
  11. Carla Carrilho10,
  12. Eliane Monteiro11,
  13. Hannah Hoover12,
  14. Edson Chivambo12,
  15. Marcos Chissano12,
  16. Hira Atif13,
  17. Rebecca Richards-Kortum9,
  18. Eva Lathrop14,
  19. Cesaltina Lorenzoni10 and
  20. Kathleen M Schmeler1
  1. 1The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, USA
  2. 2Dasa, Research and Development, Barueri, Brazil
  3. 3Eduardo Mondlane University, Obstetrics and Gynecology, Maputo, Mozambique
  4. 4Jose Macamo General Hospital, Obstetrics and Gynecology, Maputo, Mozambique
  5. 5Hospital Central de Maputo, Obstetrics and Gynecology, Maputo, Mozambique
  6. 6Hospital Geral de Mavalane, Obstetrics and Gynecology, Maputo, Mozambique
  7. 7MD Anderson Cancer Center The University of Texas, Department of Oncology Care and Research Information Systems, Houston, USA
  8. 8ICON Strategic Solutions, Research, Sao Paulo, Brazil
  9. 9Rice University, Department of Bioengeneering, Houston, USA
  10. 10Maputo Central Hospital, Pathology, Maputo, Mozambique
  11. 11Hospital Geral e Centro de Saúde de Mavalane, Pathology, Maputo, Mozambique
  12. 12Population Services International, Research, Maputo, Mozambique
  13. 13Maputo Central Hospital, Obstetrics and Gynecology, Maputo, Mozambique
  14. 14Population Services International, Global Medical Director, Washington, USA

Abstract

Introduction The objective of our study is to describe the high-risk human papillomavirus (HR-HPV) types noted among women enrolled in the MULHER Study, a prospective trial of Mozambican women undergoing cervical cancer screening with HPV testing in conjunction with family planning services.

Methods From January 2020 to January 2023, 9,014 women aged 30–49 years in Maputo City and Gaza Province, Mozambique underwent cervical cancer screening. Cervicovaginal samples were self-collected (97.5%) or provider-collected (2.5%) and primary HPV testing was performed using the GeneXpert HPV testing platform (Cepheid Inc, Sunnyvale, CA, USA) which provided genotyping for HPV16, HPV18/45 and non-16/18/45. Women with positive HPV testing underwent visual assessment for treatment (VAT) using visual inspection with acetic acid (VIA) and treated with ablation or excision as appropriate.

Results Of the 9,014 women enrolled, 2,805 (31.1%) tested positive for at least one HR-HPV type: HPV16 (n=477, 17%), HPV18/45 (n=688, 24.5%) and non-16/18/45 (2,157, 76.9%). 23.2% of participants with HR-HPV had multiple types present. HR-HPV infection was more frequently observed among women living with HIV (WLWH) compared with HIV-negative women (39.5% vs, 24.2% respectively; p<0.001), with non-16/18/45 also being the most frequent type in this population (69.6%). Among women with cancer, HPV16 was the most frequent type noted (58%).

Conclusion/Implications Our findings suggest that non-16/18/45 was the most frequent HR-HPV type among women in our study cohort in Mozambique overall; and HPV16 is the most common among women with cervical cancer. Further study is needed to determine the role of HR-HPV genotyping in follow-up and treatment, particularly among WLWH in Mozambique.

https://doi.org/10.1136/ijgc-2023-IGCS.189

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.